{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:56:46Z","timestamp":1793329006555,"version":"4.5.0"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,7,4]]},"published-print":{"date-parts":[[2024,9]]},"DOI":"10.2967\/jnumed.124.267955","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T13:05:40Z","timestamp":1723122340000},"page":"1395-1401","source":"Crossref","is-referenced-by-count":27,"title":["Impact of Posttreatment SPECT\/CT on Patient Management During\n                    <sup>177<\/sup>\n                    Lu-PSMA-617 Radiopharmaceutical Therapy"],"prefix":"10.2967","volume":"65","author":[{"given":"Surekha","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"Lowery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abuzar Moradi","family":"Tuchayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Saelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul R.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanna","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"2024090306450632000_65.9.1395.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2024090306450632000_65.9.1395.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2024090306450632000_65.9.1395.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"2024090306450632000_65.9.1395.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262543"},{"key":"2024090306450632000_65.9.1395.5","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2024090306450632000_65.9.1395.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"2024090306450632000_65.9.1395.7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/OP.22.00753","article-title":"Systemic therapy update on 177lutetium-PSMA-617 for metastatic castration-resistant prostate cancer: ASCO guideline rapid recommendation Q and A","volume":"19","author":"Garje","year":"2023","journal-title":"JCO Oncol Pract."},{"key":"2024090306450632000_65.9.1395.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2024090306450632000_65.9.1395.9","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024090306450632000_65.9.1395.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264594"},{"key":"2024090306450632000_65.9.1395.11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin Nucl Med."},{"key":"2024090306450632000_65.9.1395.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233411"},{"key":"2024090306450632000_65.9.1395.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2024090306450632000_65.9.1395.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264398"},{"key":"2024090306450632000_65.9.1395.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264677"},{"key":"2024090306450632000_65.9.1395.16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","article-title":"Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study","volume":"51","author":"Neubauer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024090306450632000_65.9.1395.17","doi-asserted-by":"crossref","first-page":"17588359231156392","DOI":"10.1177\/17588359231156392","article-title":"Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)","volume":"15","author":"Emmett","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2024090306450632000_65.9.1395.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2024090306450632000_65.9.1395.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.254656"},{"key":"2024090306450632000_65.9.1395.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263072"},{"key":"2024090306450632000_65.9.1395.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266391"},{"key":"2024090306450632000_65.9.1395.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266842"},{"key":"2024090306450632000_65.9.1395.23","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.18632\/oncotarget.12240","article-title":"Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer","volume":"8","author":"Fendler","year":"2017","journal-title":"Oncotarget."},{"key":"2024090306450632000_65.9.1395.24","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Grubm\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024090306450632000_65.9.1395.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.083"},{"key":"2024090306450632000_65.9.1395.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.9159"},{"key":"2024090306450632000_65.9.1395.27","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.euo.2022.05.003","article-title":"EAU-EANM consensus statements on the role of prostate-specific membrane antigen positron emission tomography\/computed tomography in patients with prostate cancer and with respect to [177Lu]Lu-PSMA radioligand therapy","volume":"5","author":"Fanti","year":"2022","journal-title":"Eur Urol Oncol."},{"key":"2024090306450632000_65.9.1395.28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol."},{"key":"2024090306450632000_65.9.1395.29","doi-asserted-by":"crossref","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology."},{"key":"2024090306450632000_65.9.1395.30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2024.42.4_suppl.32","article-title":"Assessing the clinical utility of rapid post-therapy whole-body digital SPECT\/CT in evaluating early treatment response of 177Lu-PSMA-617 treatment","volume":"42(suppl 4)","author":"Song","year":"2024","journal-title":"J Clin Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.267955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T09:47:20Z","timestamp":1725356840000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.267955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,3]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.2967\/jnumed.124.267955"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.267955","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}